BeiGene (BGNE) Stock

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a worldwide oncology firm planning to change its name to BeOne Medicines Ltd., has announced that the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr). This drug is now approved for use alongside platinum and fluoropyrimidine-based chemotherapy as a first-line treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ).

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a worldwide cancer treatment company, plans to change its name to BeOne Medicines Ltd. It will also update its Nasdaq ticker symbol to “ONC” on January 2, 2025, to show its dedication to providing innovative cancer medicines around the world. As the company enters its 15th year, this change highlights its strong commitment to leadership in oncology and its mission to deliver transformative treatments.

SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a worldwide oncology company planning to change its name to BeOne Medicines Ltd., has announced a global licensing deal with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. for SYH2039. This new drug is a methionine adenosyltransferase 2A (MAT2A) inhibitor that is being studied for its effectiveness against solid tumors. SYH2039 specifically targets tumors with a mutation known as MTAP deletion.

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a worldwide oncology firm that intends to rebrand as BeOne Medicines Ltd., has shared new clinical findings at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. This highlights its strong position in treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with ongoing success from BRUKINSA® (zanubrutinib) and encouraging developments in the field.

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology firm planning to change its name to BeOne Medicines Ltd., has announced an investor webcast scheduled for December 16, 2024, at 8:30 am EST. During this event, the company's R&D leadership will share updates on BeiGene's innovative portfolio and pipeline, highlighting important presentations from the American Society of Hematology Meeting (ASH) and the San Antonio Breast Cancer Symposium.

The European Commission has recently approved BeiGene's TEVIMBRA, which is set to launch in the EU after its entry into the US market in October. The company's revenue per share has seen considerable growth, and both TEVIMBRA and BRUKINSA are expected to help BeiGene become profitable in the next 12 to 18 months. Analysts predict that BeiGene's revenues will hit $4.64 billion next year, making it a strong buy with a target price of $293 per share over the next year.

SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company planning to change its name to BeOne Medicines, has announced that the European Commission has approved TEVIMBRA® (tislelizumab) to be used with chemotherapy for the initial treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. “Patients facing advanced gastric and esophageal cancers deal with significant challenges.

SAN MATEO, Calif.--(BUSINESS WIRE)-- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a worldwide oncology company planning to change its name to BeOne Medicines Ltd., has announced its participation in two upcoming investor conferences. The first is the Citizens JMP Hematology and Oncology Summit on Monday, December 2 at 1:00 p.m. ET, followed by Citi's Global Healthcare Conference on Thursday, December 5 at 9:30 a.m. ET. Investors can watch the live webcasts of these events online.

SAN MATEO, Calif. & BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a worldwide cancer treatment company, has announced plans to change its name to BeOne Medicines Ltd. This change reflects its dedication to creating new treatments aimed at eradicating cancer by collaborating with the global community to help as many patients as possible. "Cancer is a major cause of death around the world and has a significant impact on individuals, families, and communities."